Cerebral malaria (CM) can be classified as retinopathy-positive or retinopathy-negative, based on the presence or absence of characteristic retinal features. While malaria parasites are considered central to the pathogenesis of retinopathy-positive CM, their contribution to retinopathy-negative CM is largely unknown. One theory is that malaria parasites are innocent bystanders in retinopathy-negative CM and the etiology of the coma is entirely non-malarial. Because hospitals in malaria-endemic areas often lack diagnostic facilities to identify non-malarial causes of coma, it has not been possible to evaluate the contribution of malaria infection to retinopathy-negative CM. To overcome this barrier, we studied a natural experiment involving genetically inherited traits, and find evidence that malaria parasitemia does contribute to the pathogenesis of retinopathy-negative CM. A lower bound for the fraction of retinopathy-negative CM that would be prevented if malaria parasitemia were to be eliminated is estimated to be 0.93 (95% confidence interval: 0.68, 1).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462542PMC
http://dx.doi.org/10.7554/eLife.23699DOI Listing

Publication Analysis

Top Keywords

malaria parasitemia
12
natural experiment
8
malaria
8
cerebral malaria
8
malaria parasites
8
retinopathy-negative
7
evidence natural
4
experiment malaria
4
parasitemia pathogenic
4
pathogenic retinopathy-negative
4

Similar Publications

Article Synopsis
  • A 52-year-old man was admitted to the ICU in septic shock from severe malaria after traveling to Ghana, with a high parasitaemia index of 50%.
  • He was treated with intravenous artesunate and dihydroartemisinin plus piperaquine, leading to rapid clinical improvement and a 0% parasitaemia level within 72 hours, but developed severe anaemia with hemoglobin dropping to 5.6 g/dL.
  • The anaemia was diagnosed as post-artesunate haemolytic anaemia (PDAH) due to high parasitaemia and treatment, treated with oral steroids, highlighting the need for awareness of PDAH in severe malaria cases for effective recovery.
View Article and Find Full Text PDF

Background: India is committed to malaria elimination by the year 2030. According to the classification of malaria endemicity, the National Capital Territory of Delhi falls under category 1, with an annual parasite incidence of <1, and was targeted for elimination by 2022. Among others, population movement across states is one of the key challenges for malaria control, as it can result in imported malaria, thus introducing local transmission in an area nearing elimination.

View Article and Find Full Text PDF

Malaria vaccines consisting of metabolically active Plasmodium falciparum (Pf) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial.

View Article and Find Full Text PDF

The significance of multiplication rate variation in malaria parasites needs to be determined, particularly for Plasmodium falciparum, the species that causes most virulent infections. To investigate this, parasites from cases presenting to hospital in The Gambia and from local community infections were culture-established and then tested under exponential growth conditions in a standardised six-day multiplication rate assay. The multiplication rate distribution was lower than seen previously in clinical isolates from another area in West Africa where infection is more highly endemic.

View Article and Find Full Text PDF

Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei.

Int J Parasitol Drugs Drug Resist

December 2024

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21210, USA. Electronic address:

Fosmidomycin and clindamycin target the Plasmodium apicoplast. Combination clinical trials have produced mixed results with the primary problem being the recrudescent infection frequency by day 28. Given that antibiotic efficacy against bacterial infections often depends on the constant drug presence over several days, we hypothesized that the antimalarial blood or liver stage efficacy of fosmidomycin and clindamycin could be improved by implementing a more frequent dosing schedule.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!